Eksempler på bruk av Subcutaneous formulation på Engelsk og deres oversettelse til Norsk
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The interval between consecutive Herceptin subcutaneous formulation administrations should not be less than three weeks.
Intervallet mellom etterfølgende administreringer med Herceptin subkutan formulering bør ikke være mindre enn tre uker.The objective of the Part 1 was to select a MabThera subcutaneous formulation dose that resulted in comparable MabThera serum Ctrough levels compared with MabThera intravenous formulation. .
Hensikten med stadium 1 var å velge en en dose for MabThera subkutan formulering som resulterte i sammenlignbare MabThera serum Ctrough nivåer med MabThera intravenøs Post-operative wound infections(severe and/or serious): 1.7% versus 3.0% for the intravenous formulation versus subcutaneous formulation.
Post-operative sårinfeksjoner(vanskelige og/eller alvorlige): 1,7 % Results were consistent with the known safety profile for Herceptin intravenous and Herceptin subcutaneous formulations.
Ingen nye sikkerhetssignaler oppstod og resultatene var i overenstemmelse med den kjente sikkerhetsprofilen for Herceptin intravenøs The safety profile of Herceptin subcutaneous formulation(evaluated in 298 and 297 patients treated with the intravenous and subcutaneous formulations respectively) from the pivotal trial BO22227 in EBC was overall similar to the known safety profile of the intravenous formulation. .
Sikkerhetsprofilen for Herceptin subkutan formulering(vurdert hos 298 og 297 pasienter behandlet henholdsvis med intravenøs og subkutan formulering), fra den pivotale studien BO22227 for brystkreft i tidlig stadium, var generelt sammenlignbar med den kjente sikkerhetsprofilen for den intravenøse Amongst the most serious and/or common adverse reactions reported in Herceptin usage(intravenous and subcutaneous formulations) to date are cardiac dysfunction,
Blant de mest alvorlige og/eller vanlige bivirkningene rapportert ved bruk av Herceptin(intravenøse og subkutane formuleringer) per i dag er nedsatt hjertefunksjon,with a greater proportion of patients with severe events(NCI CTCAE grade≥3)< 1% versus 2.0% the intravenous and subcutaneous formulations respectively.
1 % versus 2,0 % i henholdsvis Administration-related reactions(ARRs) are known to occur with Herceptin subcutaneous formulation.
Det er kjent at administrasjonsrelaterte reaksjoner kan oppstå med Herceptin subkutan formulering.handling of Herceptin subcutaneous formulation refer to section 6.6.
håndtering av Herceptin subkutan formulering, se pkt.All of the severe ARRs with the Herceptin subcutaneous formulation occurred during concurrent administration with chemotherapy.
Alle alvorlige ARRs med Herceptin subkutan formulering oppstod ved samtidig administrasjon med docetaxel.The dose of 1600 mg of MabThera subcutaneous formulation was selected for the Part 2 of the study.
Dosen på 1600 mg MabThera subkutan formulering ble valgt til andre del av studien.The comparison of predicted median Cmax data for MabThera subcutaneous formulation and intravenous formulation are summarized in Table 7.
Sammenligning av anslått median Cmax verdier for MabThera subkutan formulering og intravenøs The safety and efficacy of RoActemra subcutaneous formulation in children from birth to less than 18 years have not been established.
Sikkerhet og effekt av RoActemra subkutan formulering hos barn fra fødsel til under 18 år har ikke blitt fastslått.Once removed from the refrigerator Herceptin subcutaneous formulation must be administered within 6 hours
Herceptin subkutan formulering skal administreres innen 6 timer etter at det er tatt ut av kjøleskap, og bør ikke oppbevaresDuring the treatment course with Herceptin subcutaneous formulation other medicinal products for subcutaneous administration should preferably be injected at different sites.
I løpet av behandlingen med Herceptin subkutan formulering bør andre legemidler til During the treatment course with MabThera subcutaneous formulation, other medicinal products for subcutaneous administration should preferably be given at different sites.
Under behandlingstiden med MabThera subkutan formulering bør andre legemidler til Pasireotide has been shown to prolong the QT interval on the ECG in two dedicated healthy volunteer studies performed with the subcutaneous formulation.
Det har blitt vist at pasireotid forlenger QT-intervallet på EKG i to dedikerte studier med friske frivillige utført med subkutan formulering.The majority of local cutaneous reactions seen following administration of MabThera subcutaneous formulation was mild
De fleste lokale hudreaksjonene sett etter administrering av MabThera subkutan formulering var milde eller moderateOverall the results confirm that MabThera subcutaneous formulation 1600 mg has a comparable benefit/risk profile to that of MabThera intravenous formulation 500 mg/m2.
Resultatene bekreftet at MabThera subkutan formulering 1600 mg har en sammenlignbar nytte/risikoprofil som MabThera intravenøs During the treatment course with Herceptin subcutaneous formulation in administration system, other medicinal products for subcutaneous administration should preferably be injected at different sites.
I løpet av behandlingen med Herceptin subkutan formulering i et administrasjonssystem bør andre legemidler til 
